Download PDF
Int J Angiol 2015; 24(01): 01-10
DOI: 10.1055/s-0034-1374808
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Surgical, Interventional, and Device Innovations in the Management of Hypertension

Sibu P. Saha
1   Division of Cardiothoracic Surgery, Gill Heart Institute, University of Kentucky, Lexington, Kentucky
,
Khaled M. Ziada
2   Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky
,
Thomas F. Whayne Jr.
2   Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky
› Author Affiliations
Further Information

Publication History

Publication Date:
12 May 2014 (online)

    Permissions and Reprints

Abstract

The prevalence of hypertension around the world has increased significantly with projections for an increasing major global burden of hypertension. Medication-resistant hypertension can be perplexing and frustrating. The existence of these difficult patients results in the need for additional approaches to treatment including surgery, percutaneous interventions, and device management. The sophistication of these techniques has progressed markedly and initial procedures such as classical sympathectomy and renal artery bypass are almost never performed. Newer techniques of angioplasty with stenting, renal artery denervation, and baroreflex activation therapy via electrical stimulation of the carotid baroreceptors are now in use with increasing evidence for significant benefit.

Keywords

hypertension - renal artery denervation - renal artery stenting - resistant hypertension - sympathectomy
 

  • References

  • 1 Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365 (9455) 217-223
    CrossrefPubMedGoogle Scholar
  • 2 Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension—United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep 2011; 60 (4) 103-108
    PubMedGoogle Scholar
  • 3 McAlister FA. The Canadian Hypertension Education Program—a unique Canadian initiative. Can J Cardiol 2006; 22 (7) 559-564
    CrossrefPubMedGoogle Scholar
  • 4 Campbell N, Young ER, Drouin D , et al. A framework for discussion on how to improve prevention, management, and control of hypertension in Canada. Can J Cardiol 2012; 28 (3) 262-269
    CrossrefPubMedGoogle Scholar
  • 5 Burroughs Peña MS, Mendes Abdala CV, Silva LC, Ordúñez P. Usefulness for surveillance of hypertension prevalence studies in Latin America and the Caribbean: the past 10 years. Rev Panam Salud Publica 2012; 32 (1) 15-21
    CrossrefPubMedGoogle Scholar
  • 6 Reklaitiene R, Tamosiunas A, Virviciute D, Baceviciene M, Luksiene D. Trends in prevalence, awareness, treatment, and control of hypertension, and the risk of mortality among middle-aged Lithuanian urban population in 1983-2009. BMC Cardiovasc Disord 2012; 12: 68
    CrossrefPubMedGoogle Scholar
  • 7 Bosu WK. Epidemic of hypertension in Ghana: a systematic review. BMC Public Health 2010; 10: 418
    CrossrefPubMedGoogle Scholar
  • 8 Haghdoost AA, Sadeghirad B, Rezazadehkermani M. Epidemiology and heterogeneity of hypertension in Iran: a systematic review. Arch Iran Med 2008; 11 (4) 444-452
    PubMedGoogle Scholar
  • 9 Schmieder RE. End organ damage in hypertension. Dtsch Arztebl Int 2010; 107 (49) 866-873
    PubMedGoogle Scholar
  • 10 Cooper-DeHoff RM, Gong Y, Handberg EM , et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304 (1) 61-68
    CrossrefPubMedGoogle Scholar
  • 11 Chobanian AV, Bakris GL, Black HR , et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42 (6) 1206-1252
    CrossrefPubMedGoogle Scholar
  • 12 Littenberg B, Garber AM, Sox Jr HC. Screening for hypertension. Ann Intern Med 1990; 112 (3) 192-202
    CrossrefPubMedGoogle Scholar
  • 13 Thompson M, Dana T, Bougatsos C, Blazina I, Norris SL. Screening for hypertension in children and adolescents to prevent cardiovascular disease. Pediatrics 2013; 131 (3) 490-525
    CrossrefPubMedGoogle Scholar
  • 14 Sacks FM, Svetkey LP, Vollmer WM , et al; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344 (1) 3-10
    CrossrefPubMedGoogle Scholar
  • 15 Robbins CL, Dietz PM, Bombard J, Tregear M, Schmidt SM, Tregear SJ. Lifestyle interventions for hypertension and dyslipidemia among women of reproductive age. Prev Chronic Dis 2011; 8 (6) A123
    PubMedGoogle Scholar
  • 16 Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23 (5) 460-468
    CrossrefPubMedGoogle Scholar
  • 17 Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009; (3) CD001841
    PubMedGoogle Scholar
  • 18 Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49 (11) 1157-1163
    CrossrefPubMedGoogle Scholar
  • 19 Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens 2012; 26 (5) 281-287
    CrossrefPubMedGoogle Scholar
  • 20 Cannon B. The effects of progressive sympathectomy on blood pressure. Am J Physiol 1931; 97 (4) 592-596
    PubMedGoogle Scholar
  • 21 Smithwick RH. Surgery in hypertension. Lancet 1948; 2 (6515) 65
    PubMedGoogle Scholar
  • 22 Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953; 152 (16) 1501-1504
    CrossrefPubMedGoogle Scholar
  • 23 Modrall JG, Rosero EB, Smith ST , et al. Operative mortality for renal artery bypass in the United States: results from the National Inpatient Sample. J Vasc Surg 2008; 48 (2) 317-322
    CrossrefPubMedGoogle Scholar
  • 24 Hu ZP, Wang ZW, Dai XF , et al. Outcomes of surgical versus balloon angioplasty treatment for native coarctation of the aorta: a meta-analysis. Ann Vasc Surg 2014; 28 (2) 394-403
    CrossrefPubMedGoogle Scholar
  • 25 Stewart AB, Ahmed R, Travill CM, Newman CG. Coarctation of the aorta life and health 20-44 years after surgical repair. Br Heart J 1993; 69 (1) 65-70
    CrossrefPubMedGoogle Scholar
  • 26 Walhout RJ, Lekkerkerker JC, Oron GH, Bennink GB, Meijboom EJ. Comparison of surgical repair with balloon angioplasty for native coarctation in patients from 3 months to 16 years of age. Eur J Cardiothorac Surg 2004; 25 (5) 722-727
    CrossrefPubMedGoogle Scholar
  • 27 Pádua LM, Garcia LC, Rubira CJ, de Oliveira Carvalho PE. Stent placement versus surgery for coarctation of the thoracic aorta. Cochrane Database Syst Rev 2012; 5: CD008204
    PubMedGoogle Scholar
  • 28 Wong D, Benson LN, Van Arsdell GS, Karamlou T, McCrindle BW. Balloon angioplasty is preferred to surgery for aortic coarctation. Cardiol Young 2008; 18 (1) 79-88
    PubMedGoogle Scholar
  • 29 Canniffe C, Ou P, Walsh K, Bonnet D, Celermajer D. Hypertension after repair of aortic coarctation—a systematic review. Int J Cardiol 2013; 167 (6) 2456-2461
    CrossrefPubMedGoogle Scholar
  • 30 Vohra HA, Adamson L, Haw MP. Does surgical correction of coarctation of the aorta in adults reduce established hypertension?. Interact Cardiovasc Thorac Surg 2009; 8 (1) 123-127
    CrossrefPubMedGoogle Scholar
  • 31 Disick GI, Munver R. Adrenal-preserving minimally invasive surgery: update on the current status of laparoscopic partial adrenalectomy. Curr Urol Rep 2008; 9 (1) 67-72
    CrossrefPubMedGoogle Scholar
  • 32 Dubel GJ, Murphy TP. The role of percutaneous revascularization for renal artery stenosis. Vasc Med 2008; 13 (2) 141-156
    CrossrefPubMedGoogle Scholar
  • 33 Abela R, Ivanova S, Lidder S, Morris R, Hamilton G. An analysis comparing open surgical and endovascular treatment of atherosclerotic renal artery stenosis. Eur J Vasc Endovasc Surg 2009; 38 (6) 666-675
    CrossrefPubMedGoogle Scholar
  • 34 Bloch MJ, Basile J. Clinical insights into the diagnosis and management of renovascular disease. An evidence-based review. Minerva Med 2004; 95 (5) 357-373
    PubMedGoogle Scholar
  • 35 Rabbia C, Pini R. Evidence-based medicine in renal artery stenting. J Cardiovasc Surg (Torino) 2010; 51 (5) 755-763
    PubMedGoogle Scholar
  • 36 Kumbhani DJ, Bavry AA, Harvey JE , et al. Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials. Am Heart J 2011; 161 (3) 622-630 , e1
    CrossrefPubMedGoogle Scholar
  • 37 Balk E, Raman G, Chung M , et al. Effectiveness of management strategies for renal artery stenosis: a systematic review. Ann Intern Med 2006; 145 (12) 901-912
    CrossrefPubMedGoogle Scholar
  • 38 Kashyap VS, Sepulveda RN, Bena JF , et al. The management of renal artery atherosclerosis for renal salvage: does stenting help?. J Vasc Surg 2007; 45 (1) 101-108 , discussion 108–109
    CrossrefPubMedGoogle Scholar
  • 39 Cooper CJ, Murphy TP, Cutlip DE , et al; CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014; 370 (1) 13-22
    CrossrefPubMedGoogle Scholar
  • 40 DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 2002; 11 (2) 197-200
    CrossrefPubMedGoogle Scholar
  • 41 Krum H, Schlaich M, Whitbourn R , et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373 (9671) 1275-1281
    CrossrefPubMedGoogle Scholar
  • 42 Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57 (5) 911-917
    CrossrefPubMedGoogle Scholar
  • 43 Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M ; Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376 (9756) 1903-1909
    CrossrefPubMedGoogle Scholar
  • 44 Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA ; Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012; 126 (25) 2976-2982
    CrossrefPubMedGoogle Scholar
  • 45 Kandzari DE, Bhatt DL, Sobotka PA , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35 (9) 528-535
    CrossrefPubMedGoogle Scholar
  • 46 O'Riordan M . Renal denervation fails in SYMPLICITY HTN-3. Available at: http://www.medscape.com/viewarticle/818938 , Accessed January 12, 2014
    PubMed
  • 47 Bunte MC, Infante de Oliveira E, Shishehbor MH. Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Interv 2013; 6 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 48 Davis MI, Filion KB, Zhang D , et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol 2013; 62 (3) 231-241
    CrossrefPubMedGoogle Scholar
  • 49 Mahfoud F, Lüscher TF, Andersson B , et al; European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34 (28) 2149-2157
    CrossrefPubMedGoogle Scholar
  • 50 Viskoper R, Shapira I, Priluck R , et al. Nonpharmacologic treatment of resistant hypertensives by device-guided slow breathing exercises. Am J Hypertens 2003; 16 (6) 484-487
    CrossrefPubMedGoogle Scholar
  • 51 Bisognano JD, Bakris G, Nadim MK , et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol 2011; 58 (7) 765-773
    CrossrefPubMedGoogle Scholar
  • 52 Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012; 6 (2) 152-158
    CrossrefPubMedGoogle Scholar
  • 53 CVRx Barostim Hypertension Pivotal Trial Available at: http://www.clinicaltrials.gov/ct2/results?term=CVRX+Barostim+Hypertension+Pivotal+Trial&Search=Search . Accessed August 21, 2013
    PubMed
  • 54 Hoppe UC, Brandt MC, Wachter R , et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012; 6 (4) 270-276
    CrossrefPubMedGoogle Scholar
  • 55 van Lill L, Malan L, van Rooyen J, Steyn F, Reimann M, Ziemssen T. Baroreceptor sensitivity, cardiovascular responses and ECG left ventricular hypertrophy in men: the SABPA study. Blood Press 2011; 20 (6) 355-361
    CrossrefPubMedGoogle Scholar
  • 56 Jordan J, Heusser K, Brinkmann J, Tank J. Electrical carotid sinus stimulation in treatment resistant arterial hypertension. Auton Neurosci 2012; 172 (1-2) 31-36
    CrossrefPubMedGoogle Scholar
  • 57 Reyes del Paso GA, Cea JI, González-Pinto A , et al. Short-term effects of a brief respiratory training on baroreceptor cardiac reflex function in normotensive and mild hypertensive subjects. Appl Psychophysiol Biofeedback 2006; 31 (1) 37-49
    CrossrefPubMedGoogle Scholar
  • 58 Raczak G. Atorvastatin reduces sympathetic activity and improves baroreceptor reflex sensitivity in patients with hypercholesterolemia and hypertension [in Polish]. Kardiol Pol 2009; 67 (6) 621-622
    PubMedGoogle Scholar
  • 59 Lewandowski J, Siński M, Bidiuk J , et al. Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertens Res 2010; 33 (10) 1038-1043
    CrossrefPubMedGoogle Scholar